Treatment of Pseudomonas aeruginosa remains challenging, despite the availability ceftolozane-tazobactam. We report a treatment failure with ceftolozane-tazobactam salvage therapy for pneumonia complicated by lung abscess. Drug resistance, dose selection, and source control are possible contributing factors. Ceftolozane-tazobactam susceptibility testing should precede therapy and consideration should be given to dosing selection.

This thesis investigates the supply chain of Vancomycin and Piperacillin/Tazobactam in order to understand why the two antibiotics have been exposed to back orders during recent years in Sweden. The health economical consequences due to these back orders of the two antibiotics was also examined. The used methods were literature search and elementary calculation methods. The supply chains for the two antibiotics consists of multiple manufacturing actors, both primary and secondary. The manufacturing actors are mostly located in low and middle income countries, which increases risks for the supply chains. The Swedish market is unattractive due to its small size and ineffective purchasing system, which also increases risks of shortages. The unattractive market is a probable cause of the lower amount of market authorisation holders which sell the antibiotics in Sweden. Furthermore, a financial model was created to assess the health economic impacts of shortages. The costs were calculated as the sum of the additional labor required to deal with shortages along with the costs of the alternative medicines. It was estimated that a shortage of Vancomycin can cost up to SEK 1 600 000 in fixed costs followed by up to SEK 202 997 per additional day of shortage and that a shortage of Pipetazo can cost up to SEK 1 600 000 in fixed costs followed by up to SEK 923 650 per day. There are also other negative aspects of these consequences, such as worsening of patient health and contributions to increased AMR.

La pipéracilline-tazobactam est une combinaison d’un antibiotique bêta-lactamine et d’un inhibiteur des bêta-lactamases fréquemment prescrite aux soins intensifs. Les patients admis aux soins intensifs présentent souvent une réponse très variable au traitement en raison des multiples changements pathophysiologiques présents dans cette population qui modifient le profil pharmacocinétique du médicament. La modélisation pharmacocinétique de population est une approche qui permet d’expliquer une partie de cette variabilité au moyen d’équations mathématiques. À l’aide d’un modèle pharmacocinétique, il est possible de décrire le devenir systémique du médicament à l’aide de paramètres clés comme la clairance et le volume de distribution. Également, ce type de modèle offre la possibilité d’effectuer des simulations de régimes posologiques pour faciliter l’atteinte des cibles thérapeutiques, dans une optique d’individualisation de la pharmacothérapie. Ce projet de maîtrise avait trois objectifs. Le premier était de documenter la variabilité associée à la pharmacocinétique de la pipéracilline-tazobactam aux soins intensifs en réalisant une revue de la littérature. Cette revue a pu relever certaines covariables significatives dans les modèles qui expliquaient une partie de la variabilité observée, comme la clairance de la créatinine et le poids. Le second avait pour but d’évaluer la performance prédictive des modèles pharmacocinétiques déjà disponibles dans la littérature pour la pipéracilline-tazobactam à l’aide d’une base de données indépendante. Parmi les modèles évalués, le meilleur a été retenu afin d’optimiser les régimes posologiques aux soins intensifs. Ainsi, grâce à ce modèle, un nomogramme prenant en considération la fonction rénale du patient a été développé pour faciliter l’atteinte des cibles thérapeutiques lors de l’administration de la pipéracilline-tazobactam. Finalement, le troisième objectif était d’évaluer l’impact d’une variation de la fraction libre de la pipéracilline-tazobactam sur la performance prédictive du modèle ainsi que son impact sur la pharmacocinétique du médicament. Cette évaluation a fait ressortir l’importance d’utiliser la concentration libre plutôt que d’utiliser la concentration totale de la pipéracilline-tazobactam pour le suivi thérapeutique, car l’assomption d’une fraction libre théorique unique pour tous les patients peut nuire à la prédiction adéquate des concentrations par un modèle pharmacocinétique en milieu clinique. / Piperacillin-tazobactam is a beta-lactam/beta-lactamase inhibitor antibiotic combination frequently prescribed in intensive care units. Admitted patients often show a large variability in treatment response due to multiple pathophysiological changes that alter the pharmacokinetic profile of the drug. Population pharmacokinetic modeling is an approach that can explain some of this variability using mathematical equations. Using a pharmacokinetic model, key parameters such as clearance and volume of distribution can be retrieved to describe the systemic exposure of the drug. Also, this type of model offers the possibility to perform simulations to find optimized dosing regimens that may facilitate the achievement of target concentrations to individualize drug therapy. This master's project had three objectives. The first was to document the variability in the pharmacokinetics of piperacillin-tazobactam in the intensive care unit by conducting a literature review. This review was able to highlight key covariates, such as creatinine clearance and body weight, that could explain the variability observed in this population. The second was to evaluate the predictive performance of pharmacokinetic models available in the literature for piperacillin-tazobactam using an independent database. Among the models evaluated, the best one was selected to offer optimized dosing regimens for critically ill patients. Thus, with this model, a nomogram that accounts for the patient's renal function was developed to facilitate the achievement of therapeutic targets of piperacillin-tazobactam. Finally, the third objective was to evaluate the impact of fluctuations in the unbound fraction of piperacillin-tazobactam on the predictive performance of the model as well as its impact on the pharmacokinetics of the drug. This evaluation highlighted the importance of using unbound piperacillin concentrations for drug monitoring over total concentrations, as applying a theoretical unbound fraction to every individual may hinder the predictive performance of pharmacokinetic model if it is used in a clinical setting.

No description available.

Under senare år har en särskilt hög resistensutveckling observerats hos gramnegativa bakterier inom familjen Enterobacteriaceae. Den främsta resistensmekanismen utgör produktion av så kallade "extended-spectrum β-lactamases" (ESBL) och särskilt oroväckande är karbapenemaser (ESBLCARBA) som har förmåga att bryta ner ett flertal olika grupper av β-laktamantibiotika. Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) har utforskats som metod för snabb detektion av karbapenemasaktivitet genom analys av nedbrytning av antibiotika. Syftet med denna studie var att utvärdera om MALDI-TOF MS kan användas som metod för att detektera enzymatisk nedbrytning av Ceftolozan/Tazobaktam samt att undersöka vilka enzymer som uppvisar nedbrytning av antibiotikan. Sju karbapenemasproducerande isolat och en β-laktamasnegativ kontrollstam användes i studien. Isolaten inkuberades 120 min respektive 270 min med antibiotika (1mg/ml) i en buffertlösning (0,08% ammoniumbikarbonat, pH 8). Efter centrifugering analyserades supernatanten med MALDI-TOF MS. Nedbrytning av Ceftolozan detekterades hos samtliga karbapenemasproducerande stammar, utom hos E. coli med NDM-1 produktion. Nedbrytningstoppar av Tazobaktam detekterades emellertid enbart hos stammar med OXA-48 och NDM-7 produktion. Tydligast nedbrytning sågs efter 120 min. För tydligare visualisering av nedbrytningstoppar bör metoden dock optimeras med avseende på matrix, buffert och antibiotikakoncentration. / In recent years, an alarming increase of antibiotic resistance has been observed in Gram-negative bacteria, classified in the family Enterobacteriaceae. The main resistance mechanism is the production of extended-spectrum β-lactamases (ESBL). Particularly worrisome is the production of carbapenemases (ESBLCARBA) due to their ability to hydrolyze a broad range of β-lactams. Recently, Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) has been investigated as a method for rapid detection of carbapenemase activity through observation of antibiotic degradation. The aim of this study was to investigate whether MALDI-TOF MS can be used as a method to detect degradation of Ceftolozane/Tazobactam as well as to examine which enzymes that possess the ability to hydrolyze the antibiotic. A total of seven carbapenemase-producing strains were used in the study. The experiment also included a β-lactamase-negative isolate as a negative control. The strains were incubated with antibiotic (1mg/ml) in a buffered solution (0,08% ammonium bicarbonate, pH 8) for 120 min and 270 min. The supernatant, after centrifugation, was analyzed by MALDI-TOF MS. All the carbapenemase-producing strains demonstrated hydrolysis of Ceftolozane, except for NDM-1 producing E. coli. However, mass peaks corresponding to the degradation of Tazobactam were only detected in strains producing OXA-48 and NDM-7. The degradation of Ceftolozane/Tazobactam was most apparent after 120 minutes. However, to better enable detection of mass peaks, further optimization is needed in regard to appropriate matrix, buffer and antibiotic concentration.

Introduktion Antibiotikaresistens är ett globalt växande problem. Till gruppen β-laktamantibiotika hör piperacillin-tazobaktam och cefotaxim som båda verkar genom att försvaga cellväggen med kovalenta bindningar till peptidoglykanlagret som lyserar cellen. E. coli och K. pneumoniae tillhör gruppen Enterobacteriaceae, som är en del av den humana tarmfloran och ofta förekommande vid urinvägsinfektion och sepsis. Utvidgat Spektrum β-Laktamas (ESBL) är ett enzym som finns hos Enterobacteriaceae och som hydrolyserar β-laktamantibiotika. Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) är en kvalitativ analysteknik för detektion av kemiska föreningar i avseende på massa och laddning. Kännedom om antibiotikametaboliters molekylvikt vid hydrolys möjliggör detektion. Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) är en högsensitiv kvantifieringsmetod som separerar molekyler i avseende på polaritet för vidare detektion i avseende på massa och laddning. Syfte Syftet med denna studie var att vidareutveckla en snabb och effektiv metod för att påvisa nedbrytning av piperacillin-tazobaktam och cefotaxim i blodplasma med LC-MS/MS. Material och Metod Tiofaldigt sjunkande koncentrationer av piperacillin-tazobaktam från 2000 till 2 µg/ml, och cefotaxim med koncentrationerna 500 till 0,5 µg/ml analyserades med MALDI-TOF MS, dels intakt men även med bakterierna E. coli och K. pneumoniae med uttryck av olika resistensmekanismer. Vid optimerade koncentrationer spikades plasmaprover med nedbrutet antibiotika som sedan kvantifierades med LC-MS/MS. Resultat Lägsta detektionsgräns med MALDI-TOF MS för intakt och hydrolyserat piperacillin-tazobaktam var 20/2,5 µg/ml. För cefotaxim var lägsta gränsen 5 µg/ml. Med kliniskt relevanta blodkoncentrationer gick hydrolys inte att detektera för. Med tre bakteriekolonier/50 µl kunde dock hydrolys detekteras och kvantifieras med LC-MS/MS. Slutsats Detektion av β-laktamantibiotika är möjligt med både MALDI-TOF MS och LC-MS/MS. För att påvisa hydrolys krävdes större mängder bakterier än förväntat med LC-MS/MS. / Introduction Antibiotic resistance is a global growing problem. Piperacillin-tazobactam and cefotaxime are parts of the group β-lactam antibiotics. The common feature is to inhibit the cell wall synthesis by covalent bindings to the peptidoglycan layer and thereby causing lysis of the bacterial cell. E. coli and K. pneumoniae are members of the Enterobacteriaceae which is a part of the human normal flora but also are commonly associated with urinary tract infections which sometimes develops into to sepsis. Extended Spectrum β-Lactamases (ESBLs) are enzymes with hydrolytic abilities acting on β-lactam antibiotics, expressed by Enterobacteriaceae. The qualitative, Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) can be used to detect chemical compounds in the ratio of mass to charge in accordance to their molecular weight. Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) is a highly sensitive two-step method of quantification which first separate molecules by their polarity attraction force and then by the ratio of mass to charge. Aim The aim of this study was to develop a fast and efficient method to determine degradation of piperacillin-tazobactam and cefotaxime in blood plasma by LC-MS/MS. Method Tenfold dilution of piperacillin-tazobactam in concentrations of 2000 to 2 µg/ml, and cefotaxime in concentrations of 500 to 0,5 µg/ml where analyzed by MALDI-TOF MS, intact and also with the bacteria E. coli and K. pneumoniae with different expression of antibiotic resistance. Optimized concentrations where fixed in blood plasma and then quantified by LC-MS/MS. Result The detection limit by using MALDI TOF MS of hydrolyzed as well as non-hydrolyzed piperacillin-tazobactam was 20/2,5 µg/ml. The detection limit in cefotaxime was 5 µg/ml. Hydrolysis could not be detected in clinically fixed blood concentrations. Detection and quantification of hydrolysis by LC-MS/MS was possible in a concentration of three bacteria colonies/50 µl. Conclusion It is possible to detect hydrolysis in both MALDI TOF MS and LC-MS/MS. A larger amount of bacteria than expected was needed to demonstrate hydrolysis In LC-MS/MS.